Trials / Recruiting
RecruitingNCT05819684
A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors
A Phase I Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4602 in HER2 Expressing or Mutated Advanced Malignant Solid Tumor Subjects
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 133 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, three-part study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-4602 and preliminary anti-tumor efficacy in HER2 expressing or mutated advanced malignant solid tumor subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-4602 for injection | be administered via intravenous (IV) infusion |
Timeline
- Start date
- 2023-04-18
- Primary completion
- 2025-05-30
- Completion
- 2026-05-30
- First posted
- 2023-04-19
- Last updated
- 2024-06-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05819684. Inclusion in this directory is not an endorsement.